2017 ASX Announcments


Below are the Company's ASX announcements for 2017


22/12/2017

Change of Director's Notice Interest - Halasz

19/12/2017

Cleansing Statement and Appendix 3B

15/12/2017

Cellmid Placement to Strategic Investor

07/12/2017

Cellmid Secures New US Retail Partner for évolis®

05/12/2017

Cellmid Capital Structure Post Consolidation

28/11/2017

YPB and Cellmid Sign Agreement to Access Chinese Consumer Health Market

24/11/2017

Change of Auditor

23/11/2017

Update - Consolidation split/CDY

23/11/2017

Results of Annual General Meeting

23/11/2017

AGM Presentation to Shareholders

16/11/2017

Appendix 3B - Unlisted Options

15/11/2017

ASIC Form 484

15/11/2017

Change of Director's Notice - Halasz

15/11/2017

Appendix 3E and 3F

1/11/2017

Change of Director's Interest Notice - Cross

1/11/2017

Change of Director's Interest notice - Walton

31/10/2017

Initial Director's Interest Notice

31/10/2017

Change of Director's Interest Notice - King

31/10/2017

Change of Director's Interest Notice - Halasz

31/10/2017

Cellmid presents at world congress for hair research

26 Oct 2017

Cellmid opens first concept store in Tokyo

25 Oct 2017

Announcement of buy-back - Appendix 3C

25 Oct 2017

Appendix 4C - quarterly

24 Oct 2017

Proposed Consolidation of Securities

23 Oct 2017

Consolidation/split - CDY

23 Oct 2017

Cellmid Annual Report to Shareholders

23 Oct 2017

Notice of Annual General Meeting/Proxy form

16 Oct 2017

Cellmid Appoints Dr Martin Cross as Non-Executive Director  

12 Oct 2017

Date of Annual General Meeting

03 Oct 2017

Cellmid Receives $947K R&D Tax Credit

03 Oct 2017

Cellmid to Present at Proactive Investors Event

27 Sep 2017

2017 FY Results Investor Presentation

25 Sep 2017

Change of Share Registry Details

30 Aug 2017

Appendix 4E

21 Aug 2017

Cellmid Completes US Consumer Study

03 Aug 2017

Cellmid Secures US Premium Retail for evolis

01 Aug 2017

Cellmid Receives Chinese Import Permits

28 Jul 2017

Notes to Appendix 4C

03 Jul 2017

Nature Paper: MK in Melanoma

19 Apr 2017

Notes to Appendix 4C

16 Mar 2017

Change of Director's Interest Notice - Maria Halasz

02 Mar 2017

Cellmids FGF5 Inhibitor Clinical Study Published

01 Mar 2017

Cellmid to Refinance R&D Loan Facility

28 Feb 2017

Appendix 4D and Half Year Accounts

07 Feb 2017 

European Midkine Alopecia Patent Allowed

31 Jan 2017

USA Midkine Alopecia Patent Allowed

24 Jan 2017

Notes to Appendix 4C

18 Jan 2017

Cellmid Receives Australian Government Grant For Midkine Programme

18 Jan 2017 

Change of Director's Interest Notice - Maria Halasz